Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Buys 15,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour purchased 15,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average cost of $3.96 per share, for a total transaction of $59,400.00. Following the completion of the acquisition, the chief executive officer directly owned 3,148,000 shares in the company, valued at $12,466,080. The trade was a 0.48% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neonc Technologies Price Performance

NTHI stock traded down $0.47 during trading on Tuesday, reaching $3.31. 285,988 shares of the company were exchanged, compared to its average volume of 104,731. The company has a 50-day moving average of $4.04 and a two-hundred day moving average of $5.27. Neonc Technologies Holdings, Inc. has a twelve month low of $3.01 and a twelve month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last posted its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NTHI. BTIG Research restated a “buy” rating and set a $15.00 price objective on shares of Neonc Technologies in a research report on Tuesday, September 8th. Maxim Group assumed coverage on Neonc Technologies in a research note on Monday, May 18th. They set a “buy” rating and a $20.00 price target on the stock. Wall Street Zen cut Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Alliance Global Partners started coverage on Neonc Technologies in a research note on Tuesday, May 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

Institutional Investors Weigh In On Neonc Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after acquiring an additional 11,108 shares during the last quarter. Westmount Partners LLC boosted its holdings in Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after acquiring an additional 153,858 shares during the last quarter. BlackRock Inc. bought a new stake in Neonc Technologies in the second quarter valued at approximately $815,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies in the 2nd quarter worth approximately $126,000.

Neonc Technologies News Summary

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.